X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IZERVAY™ (avacincaptad pegol intravitreal solution), a complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Lead Product(s): Avacincaptad Pegol
Therapeutic Area: Ophthalmology Product Name: Izervay
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Izervay (avacincaptad pegol intravitreal solution) act as completent C5 inhibitor that is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Lead Product(s): Avacincaptad Pegol
Therapeutic Area: Ophthalmology Product Name: Izervay
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Astellas Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2023
Details:
Through the acquisition, Astellas expands its ophthalmology pipeline through Iveric Bio's promising programs, including Zimura (avacincaptad pegol), an important program for Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).
Lead Product(s): Avacincaptad Pegol
Therapeutic Area: Ophthalmology Product Name: Zimura
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $5,900.0 million Upfront Cash: $5,900.0 million
Deal Type: Acquisition July 11, 2023
Details:
Through the acquisition, Astellas will expand its ophthalmology pipeline through Iveric Bio's promising programs, including Zimura (avacincaptad pegol), an important program for Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).
Lead Product(s): Avacincaptad Pegol
Therapeutic Area: Ophthalmology Product Name: Zimura
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $5,900.0 million Upfront Cash: $5,900.0 million
Deal Type: Acquisition April 30, 2023
Details:
Zimura (avacincaptad pegol) is a novel complement C5 protein inhibitor having the potential to decrease activity of the complement system that causes the degeneration of retinal cells and potentially slow the progression of geographic atrophy.
Lead Product(s): Avacincaptad Pegol
Therapeutic Area: Ophthalmology Product Name: Zimura
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
Zimura (avacincaptad pegol) is a novel complement C5 protein inhibitor by targeting C5, ACP has the potential to decrease activity of the complement system that causes the degeneration of retinal cells and potentially slow the progression of GA.
Lead Product(s): Avacincaptad Pegol
Therapeutic Area: Ophthalmology Product Name: Zimura
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
Opus Genetics' AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies.
Lead Product(s): AAv-based Gene Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Opus Genetics
Deal Size: Undisclosed Upfront Cash: $0.5 million
Deal Type: Acquisition December 28, 2022
Details:
Zimura (avacincaptad pegol), is an investigational drug that has not yet been evaluated by any regulatory body for safety and efficacy. ACP is not authorized for any indication in any country.
Lead Product(s): Avacincaptad Pegol
Therapeutic Area: Ophthalmology Product Name: Zimura
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
Zimura (ACP) is novel complement C5 protein inhibitor. Overactivity of the complement system and the C5 protein are suspected to play a critical role in development and growth of scarring and vision loss associated with GA secondary to AMD.
Lead Product(s): Avacincaptad Pegol
Therapeutic Area: Ophthalmology Product Name: Zimura
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
Zimura (avacincaptad pegol) showed Primary Endpoint Met with 14.3% Reduction (p-value = 0.0064) in Mean Rate of Growth (Slope) in GA Area Over 12 Months Using Square Root Transformation; 17.7% Reduction (p-value = 0.0039) Using Observed GA Area
Lead Product(s): Avacincaptad Pegol
Therapeutic Area: Ophthalmology Product Name: Zimura
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
